DESVENLAFAXINE SANDOZ desvenlafaxine 100mg modified release tablets bottle
Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
Summary of Product characteristics
(SPC)
24-08-2020
Public Assessment Report
(PAR)
26-11-2017
Send request.
Active ingredient:
desvenlafaxine, Quantity: 100 mg
Available from:
Medis Pharma Pty Ltd
INN (International Name):
Desvenlafaxine
Pharmaceutical form:
Tablet, modified release
Composition:
Excipient Ingredients: purified talc; microcrystalline cellulose; alginic acid; magnesium stearate; hypromellose; povidone; citric acid monohydrate; titanium dioxide; macrogol 8000; iron oxide red; iron oxide black
Administration route:
Oral
Units in package:
1000, 14, 7, 28
Prescription type:
(S4) Prescription Only Medicine
Therapeutic indications:
For the treatment of major depressive disorder, including the preventiton of relapse. Not indicated for paediatric use.
Product summary:
Visual Identification: Dark brown to red colored, diamond shaped, biconvex tablets, debossed with 'Ll90' on one side and plain on other side.; Container Type: Bottle; Container Material: HDPE; Container Life Time: 4 Years; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure
Authorization status:
Licence status A
Authorization date:
2014-11-26
Summary of Product characteristics
_Product Information Page 1 _
_Desvenlafaxine Sandoz 50 mg, 100 mg tablet _
_04/2019 _
_Sandoz Pty Ltd _
_Version 11 Nov 2019 _
AUSTRALIAN PRODUCT INFORMATION - DESVENLAFAXINE
SANDOZ
®
(DESVENLAFAXINE) 50MG, 100MG TABLET
1.
NAME OF THE MEDICINE
Desvenlafaxine
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Two strengths of DESVENLAFAXINE SANDOZ tablets are available,
containing 50 mg and 100
mg of desvenlafaxine.
For the full list of excipients, see section 6.1 List of excipients
3.
PHARMACEUTICAL FORM
DESVENLAFAXINE SANDOZ is formulated as a modified release tablet for
once-a-day oral
administration.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Treatment of major depressive disorder, including the prevention of
relapse. Not indicated for
paediatric use.
4.2
DOSE AND METHOD OF ADMINISTRATION
Desvenlafaxine should be taken
at approximately the same
time each day. Tablets
must be
swallowed whole with fluid and not divided, crushed, chewed, or
dissolved.
_INITIAL TREATMENT_
The recommended dose for desvenlafaxine is 50 mg once daily, with or
without food. In clinical
trials, no additional benefit was demonstrated at doses greater than
50 mg/day. Based on clinical
judgment, if dose increases are indicated for individual patients,
they should occur gradually and at
intervals of not less than 7 days. The maximum dose should not exceed
200 mg/day.
When discontinuing therapy, gradual dose reduction is recommended
whenever possible to minimise
discontinuation symptoms (see Section 4.4
SPECIAL WARNINGS AND PRECAUTIONS FOR
USE
and Section 4.8
ADVERSE EFFECTS (UNDESIRABLE EFFECTS))
.
_MAINTENANCE/CONTINUATION/EXTENDED TREATMENT_
It is generally agreed that acute episodes of major depressive
disorder require several months or
_Product Information Page 2 _
_Desvenlafaxine Sandoz 50 mg, 100 mg tablet _
_04/2019 _
_Sandoz Pty Ltd _
_Version 11 Nov 2019 _
longer of sustained pharmacological therapy. Patients should continue
on the same dose at which
they were stabilised. They should be periodically reassessed to
determine the
Read the complete document
